DUBLIN – Pharmaceutical firms operating in Europe are breaching on a weekly basis their own voluntary code for regulating drug promotion, according to a recently published analysis, which calls for tougher financial penalties, stricter monitoring of drug companies' behavior and public naming and shaming of offenders.